Shares of OraSure Technologies, Inc. (NASDAQ:OSUR) have received a consensus rating of “Hold” from the seven brokerages that are covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating on the company. The average 1 year target price among brokers that have covered the stock in the last year is $16.00.
A number of analysts have recently issued reports on OSUR shares. Canaccord Genuity reaffirmed a “buy” rating and issued a $16.00 price objective on shares of OraSure Technologies in a research report on Thursday, February 7th. ValuEngine cut OraSure Technologies from a “hold” rating to a “sell” rating in a research report on Monday, February 4th. Finally, BidaskClub cut OraSure Technologies from a “hold” rating to a “sell” rating in a research report on Friday, April 5th.
In other news, CEO Stephen S. Phd Tang sold 16,667 shares of the stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $11.10, for a total transaction of $185,003.70. Following the transaction, the chief executive officer now owns 135,627 shares in the company, valued at $1,505,459.70. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 1.70% of the stock is currently owned by company insiders.
OSUR opened at $9.70 on Friday. OraSure Technologies has a 12-month low of $8.75 and a 12-month high of $18.20. The company has a market capitalization of $587.00 million, a PE ratio of 19.40, a price-to-earnings-growth ratio of 3.69 and a beta of 1.17.
OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings data on Wednesday, February 6th. The medical instruments supplier reported $0.20 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.11 by $0.09. OraSure Technologies had a return on equity of 8.45% and a net margin of 11.22%. The company had revenue of $50.25 million during the quarter, compared to analysts’ expectations of $47.77 million. During the same period last year, the firm posted $0.12 earnings per share. The business’s revenue was down 3.4% on a year-over-year basis. Sell-side analysts anticipate that OraSure Technologies will post 0.2 EPS for the current year.
OraSure Technologies Company Profile
OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.